Oncorine (H101) plus tislelizumab and platinum-based two-drug chemotherapy in previously untreated advanced non-small cell lung cancer, a phase II single-arm clinical trail

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061305

Enrollment

Unknown

Registered

2022-06-20

Start date

2022-06-20

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

one:H101

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Fully informed about this study and voluntarily signed the informed consent form (ICF); >= 18 years of age and <= 75 years of age; ECOG score 0-1; non-small cell lung cancer (NSCLC) confirmed by histology or pathology; stage IV on imaging assessment; no EGFR or ALK gene mutations (patients with squamous lung cancer may not undergo genetic testing); no prior NSCLC-specific No prior antitumor therapy for NSCLC; lesions suitable for intratumoral drug injection; measurable or evaluable lesions according to RECIST 1.1 criteria.

Exclusion criteria

Exclusion criteria: 1. tumor histology or cytologic pathology confirmed as combined small cell lung cancer component; 2. those whose examination suggests severe organ dysfunction; 3. exclude subjects with any active, known or suspected autoimmune disease; 4. Expected survival of less than 3 months.

Design outcomes

Primary

Measure	Time frame
progression-free survival;	—

Secondary

Measure	Time frame
Objective Response Rate;disease control rate;	—

Countries

China

Contacts

Public ContactZhiyong He

Fujian Cancer Hospital

heyong1015@163.com+86 13805086391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026